Executive officers

James McCullough, MBA, CEO

James McCullough has served as our co-founder and Chief Executive Officer since our inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.

Fergus Fleming, CTO

Fergus Fleming has served as our Chief Technical Officer since our inception. Mr. Fleming has served as managing director of FF Consulting Limited, providing Product Development and Commercialization support to Medical Devices and Diagnostics companies since June 2013. Roles in this period include Head of Business Development for Oncomark Limited from November 2016 to October 2018 and from 2013, he served in various roles at EKF Diagnostics plc. He has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.

Thomas McLain, MBA, CPA, President

Thomas McLain has served as our President since July 2019. Prior to joining Renalytix AI, he held leading positions, including as Chief Executive Officer, of Exosome Diagnostics Inc. from July 2014 to July 2019. Mr. McLain has also served as President and Chief Executive Officer of Vermillion, Inc., Chief Executive Officer of Claro Scientific LLC, Chairman, Chief Executive Officer and President of Nabi Biopharmaceuticals and Vice President at Bausch & Lomb. Mr. McClain received his B.A. in Economics at College of the Holy Cross and his MBA at the William E. Simon Graduate School of Business Administration at University of Rochester.

O. James Sterling, MBA, CFO

O. James Sterling, MBA, has served as our Chief Financial Officer since our inception. Since May 2015, Mr. Sterling has also served as a managing partner of Renwick Capital, LLC. Previously, he served as a managing director at SF Sentry Securities, Brock Capital Group LLC and Aleutian Capital Group. Mr. Sterling also has experience as a management consultant at Booz Allen Hamilton. He received his B.A. in geography (alternative energy and environmental science) from Boston University and an MBA from Columbia Business School.

Michael J. Donovan, PhD, MD

Michael J. Donovan, Ph.D., M.D. has served as our Chief Medical Officer since our inception. Since November 2011, Donovan has also served as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mount Sinai. In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan received a B.S. in Zoology, an M.S. in Endocrinology and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his M.D. from the University of Medicine and Dentistry of New Jersey.

Sally Bowden - Head of Regulatory Affairs and CBO

Sally Bowden has served as our Head of Regulatory Affairs since November 2018. Since July 2009, Ms. Bowden has also served as President and Chief Executive Officer of Bowden Consulting Group (formerly, Samco and Associates), which advises on FDA and global regulatory compliance. Ms. Bowden has over twenty-five years of experience in the quality and regulatory field in medical devices. She has served in executive positions as Vice President Regulatory, Quality and Operations at Vigilant Biosciences, Vice President of Quality and Process Improvement at Ventana Medical Systems and as Vice President of Quality and Regulatory Compliance at Roche Diagnostics Corporation. She has served as an Associate Professor for Purdue University School of Engineering and Technology, Indianapolis where she developed the Quality Management Curriculum within the Mechanical Engineering Technology department. Ms. Bowden received her B.S. in Industrial Engineering at Purdue University and her MBA at Indiana Wesleyan University.

Non-executive directors

Christopher Mills

Christopher Mills has served as a member of our board of directors since our inception. Mr. Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management, which he co-founded in 1993. He is chief executive officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and chairman and chief executive officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.

Erik Lium, PhD

Erik Lium, Ph.D. has served as a member of our board of directors since November 2018. Since March 2014, Dr. Lium has served in various roles at Mount Sinai, where he is currently the president of Mount Sinai Innovation Partners, and the executive vice president and chief commercial innovation officer of the Mount Sinai Health System. Dr. Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Dr. Lium also serves as chairman of the board of managers of Kantaro. Prior to joining Mount Sinai, Dr. Lium served as the assistant vice chancellor of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF), the UCSF principal investigator for the Bay Area National Science Foundation I-Corps node, and assistant vice chancellor of Research. Dr. Lium served as president of LabVelocity Inc. prior to its acquisition in 2004. He pursued postdoctoral research at UCSF in the laboratory of J. Michael Bishop, M.D., earned a Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein, and holds a B.S. in Biology from Gonzaga University.

Barbara Murphy, MD

Barbara Murphy, M.D. has served as a member of our board of directors since November 2018. Since 2013, Dr. Murphy has served as the Murray M. Rosenberg Professor of Medicine, chair of the Department of Medicine for Mount Sinai and Dean for Clinical Integration and Population Health. Her area of interest is transplant immunology, focusing on the use of high throughput genomic technologies as a means to understand the immune mechanisms that lead to graft injury and loss, with the aim of identifying gene expression profiles and or genetic variants that may be used to predict those at greatest risk. Dr. Murphy belongs to a number of professional societies including the American Society of Transplantation and the American Society of Nephrology, and has held many leadership roles at a national level. She is a past President of the American Society of Transplantation and is currently on Council for the American Society of Nephrology. Dr. Murphy earned her M.B. B.A.O. B.Ch. from The Royal College of Surgeons in Ireland and completed her postdoctoral training with a fellowship in Nephrology at Brigham and Women’s Hospital, Harvard Medical School.

Chirag R Parikh, MD, PhD

Chirag R. Parikh, Ph.D., M.D. has served as a member of our board of directors since October 2019. Since July 2018, Dr. Parikh has served as a Professor of Medicine and the Division Director of Nephrology at Johns Hopkins University. Dr. Parikh also served a faculty member at Yale University where he directed the Program of Applied Translational Research. Dr. Parikh’s research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of kidney diseases. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers. Dr. Parikh received his medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India and subsequently completed his Nephrology fellowship and a Ph.D. in Clinical Investigation at the University of Colorado Health Sciences Center.

Company Secretary

Salim Hamir, FCA

Chartered Accountant, Company Secretary and Head of Corporate Affairs EKF Diagnostics Holdings Plc

Scientific Advisory Board

Chirag R Parikh, MD, PhD, Chair

Director, Division of Nephrology, Ronald Peterson Professor of Medicine, Johns Hopkins School of Medicine

Steve Coca, DO, co-Founder

Associate Professor, Medicine, Nephrology; Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, Mount Sinai Health System

Girish Nadkarni, MD, co-Founder

Assistant Professor of Medicine, Division of Nephrology; Clinical Director of the Charles Bronfman Institute for Personalized Medicine Mount Sinai Health System

Judy Cho, MD

Director and Associate Dean for Precision Medicine, Ward-Coleman Professor of Translational Genetics and Medicine Mount Sinai Health System

John Quackenbush, PhD

Professor of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health; Professor of Cancer Biology, Dana-Farber Cancer Institute

Joseph V. Bonventre, MD, PhD

Samuel A. Levine Professor of Medicine, Harvard Medical School. Chief of the Division of Renal Medicine and Chief of the Biomedical Engineering Division, Brigham and Women’s Hospital (BWH)

Barry Freedman, MD, FACP

John H. Felts, III Professor of Medicine and Chief of the Section on Nephrology and Executive Director of the Kidney and Dialysis Service, Wake Forest Baptist Health

Jonathan Himmelfarb, MD

Professor Division of Nephrology University of Washington, Director Kidney Research Institute, Director, Center for Dialysis Innovation, Director Kidney Precision Medicine Project

Joseph Vassalotti, MD, FASN

Chief Medical Officer, National Kidney Foundation, Associate Clinical Professor of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai

George Bakris, MD

Professor of Medicine, University of Chicago, Director, Comprehensive Hypertension Center, Member Board of Directors National Kidney Foundation

John Cijiang He, MD, PhD

Professor of Medicine and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai, Irene and Dr. Arthur Fishberg endowed chair of Nephrology, Chief of Nephrology at Mount Sinai Health System.

Christian P. Larsen, MD, Dphil

Professor of Surgery, Division of Transplantation, Department of Surgery and the former dean, Emory School of Medicine; founding Director of the Emory Transplant Center


Nominated Adviser

Stifel Nicolaus Europe Limited
150 Cheapside

Joint Broker

Stifel Nicolaus Europe Limited
150 Cheapside


2 Gresham Street

Legal Advisers to the Company

Cooley (UK) LLP
69 Old Broad Street

Auditors and Reporting Accountants

PKF Littlejohn LLP
1 Westferry Circus
Canary Wharf
E14 4HD

Media & Investor Relations

Walbrook PR Limited
4 Lombard Street

Tel: +44 (0)20 7933 8780


Link Asset Services
The Registry
34 Beckenham Road

Tel: 0871 664 0300
Email: shareholderenquiries@linkgroup.co.uk
Website: www.linkassetservices.com

latest News


KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients

Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients.. Read More →

Total Voting Rights

As of 31 July 2020, the Company's issued and fully paid share capital consists of 72,029,634 ordinary shares with a nominal value of £0.0025 each,.. Read More →

Over allotment option exercise raises an additional US$10.9m

Renalytix AI plc announces that the underwriters of its global offering of new ordinary shares.. Read More →